**Amendments to the Claims**

1. (Original) A polypeptide comprising

(i) a leader sequence, the leader sequence comprising

(a) a secretion pre sequence, and

(b) the following motif :

$$-X_1-X_2-X_3-X_4-X_5-$$

where $X_1$ is phenylalanine, tryptophan, or tyrosine, $X_2$ is isoleucine, leucine, valine, alanine or methionine, $X_3$ is leucine, valine, alanine or methionine, $X_4$ is serine or threonine and $X_5$ is isoleucine, valine, alanine or methionine ; and

(ii) a desired protein heterologous to the leader sequence.

2. (Original) A polypeptide according to Claim 1 wherein $X_1$ is phenylalanine.

3. (Currently amended) A polypeptide according to Claim 1 ~~or 2~~ wherein $X_2$ is isoleucine.

4. (Currently amended) A polypeptide according to Claim 1 ~~any one of the preceding claims~~ wherein $X_3$ is valine.

5. (Currently amended) A polypeptide according to Claim 1 ~~any one of the preceding claims~~ wherein the amino acids of the motif are included in the polypeptide as substitutes, for naturally occurring amino acids.

6. (Currently amended) A polypeptide according to Claim 1 ~~any one of the preceding claims~~ wherein $X_5$ is isoleucine.

7. (Currently amended) A polypeptide according to Claim 1 ~~any one of the preceding claims~~ wherein the motif is -Phe-Ile-Val-Ser-Ile-.

8. (Currently amended) A polypeptide according to Claim 1 ~~any one of the preceding claims~~ wherein the secretion pre sequence is an albumin secretion pre sequence or a variant thereof.

9. (Currently amended) A polypeptide according to Claim 8 wherein $X_1$, $X_2$, $X_3$, $X_4$ and $X_5$ are at positions -20, -19, -18, -17 and -16, respectively, in place of the naturally occurring amino acids at those positions, wherein the numbering is such that the -1 residue is the C-terminal amino acid of the native albumin secretion pro sequence and where $X_1$, $X_2$, $X_3$, $X_4$ and $X_5$ are amino acids as defined in ~~any one of Claims~~ Claim 1 ~~to 7~~.

10. (Currently amended) A polypeptide according to Claim ~~8 or~~ 9 wherein the albumin secretion pre sequence or variant thereof is a human albumin secretion pre sequence or a variant thereof.

11. (Original) A polypeptide according to Claim 10 comprising the secretion pre sequence MKWVFIVSILFLFSSAYS.

12. (Currently amended) A polypeptide according to Claim 1 ~~any one of the preceding claims~~ wherein the leader sequence comprises a secretion pro sequence.

13. (Currently amended) A polypeptide according to Claim 12 wherein the ~~albumin~~ secretion pre sequence or variant thereof is fused by a peptide bond at its C-terminal end to the N-terminal amino acid of a secretion pro sequence, or variant thereof, thereby to form a pre-pro sequence.

14. (Currently amended) A polypeptide according to Claim ~~12 or~~ 13 wherein the secretion pro sequence is an albumin secretion pro sequence or variant thereof.

15. (Original) A polypeptide according to Claim 14 wherein the albumin secretion pro sequence is human serum albumin secretion pro sequence or variant thereof.

16. (Currently amended) A polypeptide according to Claim ~~14 or~~ 15 wherein the secretion pro sequence motif is the yeast MFα-1 secretion pro sequence or variant thereof.

17. (Original) A polypeptide according to Claim 12 comprising the sequence:

MKWVFIVSILFLFSSAYSRY$^1$Y$^2$Y$^3$Y$^4$Y$^5$

wherein Y$^1$ is Gly or Ser, Y$^2$ is Val or Leu, Y$^3$ is Phe or Asp, Y$^4$ is Arg or Lys and Y$^5$ is Arg or Lys, or variants thereof.

18. (Original) A polypeptide according to Claim 17 wherein Y$^1$ is Gly, Y$^2$ is Val and Y$^3$ is Phe; or Y$^1$ is Ser, Y$^2$ is Leu and Y$^3$ is Asp.

19. (Currently amended) A polypeptide according to Claim 17 ~~or 18~~ wherein Y$^4$ is Arg and Y$^5$ is Arg; Y$^4$ is Lys and Y$^5$ is Arg; Y$^4$ is Lys and ~~Y~~ Y$^5$ is Lys; or Y$^4$ is Arg and Y$^5$ is Lys.

20. (Currently amended) A polypeptide according to Claim 1 ~~any one of claims 1 to 7~~ wherein at least part of said motif is present in the secretion pre-sequence.

21. (Currently amended) A polypeptide according to Claim 1 ~~any one of the preceding~~

~~claims~~ wherein the sequence of the desired protein is fused at its N-terminal end to the C-terminal amino acid of the leader sequence.

22. (Currently amended) A polypeptide according to Claim 1 ~~any one of the preceding claims~~ where the desired protein is albumin or a variant, fragment or fusion thereof.

23. (Original) A polypeptide according to Claim 22 wherein the albumin is human albumin.

24. (Currently amended) A polypeptide according to ~~any one of Claims 1 to~~ Claim 21 wherein the mature polypeptide is transferrin or a variant, fragment or fusion thereof.

25. (Original) A polypeptide according to Claim 24 wherein the transferrin is human transferrin.

26. (Currently amended) An isolated polynucleotide comprising a sequence that encodes the motif defined by Claim 1 ~~any preceding claim~~.

27. (Original) A polynucleotide according to Claim 26 comprising the sequence of SEQ ID No. 15.

28. (Original) A polynucleotide according to Claim 26 comprising the sequence of SEQ ID No. 16.

29. (Original) A polynucleotide according to Claim 26 comprising the sequence of SEQ ID No. 17.

30. (Original) A polynucleotide according to Claim 26 comprising the sequence of SEQ ID No. 18.

31. (Original) A polynucleotide according to Claim 26 comprising the sequence of SEQ ID No. 34.

32. (Currently amended) A polynucleotide according to Claim 30 ~~or 31~~ comprising the sequence of SEQ ID No. 24.

33. (Original) A polynucleotide according to Claim 32 comprising the sequence of SEQ ID No. 25 or a variant thereof, which variant has the leader sequence of SEQ ID No. 24 and encodes a variant or fragment of the albumin encoded by SEQ ID No. 25.

34. (Currently amended) A polynucleotide according to Claim 30 ~~or 31~~ comprising the sequence of SEQ ID No. 27.

35. (Original) A polynucleotide according to Claim 34 comprising the sequence of SEQ ID No. 21 or a variant thereof, which variant has the leader sequence of SEQ ID No. 27 and encodes a variant or fragment of the albumin encoded by SEQ ID No. 21.

36. (Original) A polynucleotide comprising the sequence of SEQ ID No. 21 or fragment thereof.

37. (Currently amended) A polynucleotide according to any one of Claim ~~Claims~~ 33~~, 35 or 36~~ wherein the polynucleotide comprises a DNA sequence being a contiguous or non-contiguous fusion of a DNA sequence encoding a heterologous protein with either the DNA sequence SEQ ID No. 25 or the DNA sequence SEQ ID No. 21.

38. (Currently amended) A polynucleotide which is the complementary strand of a polynucleotide according to ~~any one of claims~~ Claim 26 ~~to 37~~.

39. (Currently amended) A polynucleotide according to ~~any one of Claims~~ Claim 26 ~~to 38~~ comprising an operably linked transcription regulatory region.

40. (Original) A polynucleotide according to Claim 39 wherein the transcription regulatory region comprises a transcription promoter.

41. (Currently amended) A self-replicable polynucleotide sequence comprising a polynucleotide according ~~any one of Claims~~ to Claim 26 ~~to 40~~.

42. (Currently amended) A cell comprising a polynucleotide according to ~~any one of Claims~~ Claim 26 ~~to 41~~.

43. (Original) A cell according to Claim 42 which is a eukaryotic cell.

44. (Original) A cell according to Claim 43 which is a fungal cell.

45. (Original) A cell according to Claim 44 which is an *Aspergillus* cell

46. (Original) A cell according to Claim 44 which is a yeast cell.

47. (Original) A cell according to Claim 46 which is a *Saccharomyces*, *Kluyveromyces*, *Schizosaccharomyces* or *Pichia* cell.

48. (Currently amended) A cell culture comprising a cell according to ~~any one of Claims~~ Claim 42 ~~to 47~~ and culture medium.

49. (Currently amended) A cell culture according to Claim 48 wherein the medium contains a mature desired protein as a result of the production of a polypeptide as defined in ~~any one of Claims~~ Claim 1 ~~to 22~~.

50. (Currently amended) A process for producing a mature desired protein, comprising (1) culturing a cell according to ~~any one of Claims~~ Claim 42 ~~to 47~~ in a culture medium wherein the cell, as a result of the production of a polypeptide as defined in ~~any one of Claims~~ Claim 1 ~~to 25~~, secretes a mature desired protein into the culture medium, and (2) separating the culture medium, containing the secreted mature protein, from the cell.

51. (Currently amended) A process according to Claim 50 additionally comprising the step of separating the mature desired protein from the medium ~~and optionally further purifying the mature desired protein~~.

52. (Currently amended) A process according to Claim 51 additionally comprising the step of formulating the ~~thus~~ separated ~~and/or purified~~ mature desired protein with a

therapeutically acceptable carrier or diluent thereby to produce a therapeutic product suitable for administration to a human or an animal.

53. (New) A polynucleotide according to any one of Claim ~~Claims 33,~~ 35 ~~or 36~~ wherein the polynucleotide comprises a DNA sequence being a contiguous or non-contiguous fusion of a DNA sequence encoding a heterologous protein with either the DNA sequence SEQ ID No. 25 or the DNA sequence SEQ ID No. 21.

54. (New) A polynucleotide according to any one of Claim ~~Claims 33, 35 or~~ 36 wherein the polynucleotide comprises a DNA sequence being a contiguous or non-contiguous fusion of a DNA sequence encoding a heterologous protein with either the DNA sequence SEQ ID No. 25 or the DNA sequence SEQ ID No. 21.

55. (New) A process according to Claim 51 additionally comprising the step of further purifying the mature desired protein.

56. (New) A process according to Claim 55 additionally comprising the step of formulating the thus separated and purified mature desired protein with a therapeutically acceptable carrier or diluent thereby to produce a therapeutic product suitable for administration to a human or an animal.